Annual report
3151.TEDINET S100W0QI
Period2024-04-01 → 2025-03-31
Filed2025-06-20
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Amended by S100W2SK (2025-06-23). Amended by S100WA49 (2025-07-01). Amended by S100WBYI (2025-07-09).
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥600.4bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales |
| Revenue | ¥587.5bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales |
| Revenue | ¥581.3bn | 2022-04-01 → 2023-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥578.8bn | 2021-04-01 → 2022-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥538.5bn | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥5.7bn | 2024-04-01 → 2025-03-31 | Cons. | Operating income |
| Operating income | ¥5.6bn | 2023-04-01 → 2024-03-31 | Cons. | Operating income |
| Ordinary income | ¥7.0bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥6.6bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥6.0bn | 2022-04-01 → 2023-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥5.8bn | 2021-04-01 → 2022-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥693m | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥10.7bn | 2024-04-01 → 2025-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥8.7bn | 2023-04-01 → 2024-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥7.3bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥5.8bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥4.8bn | 2022-04-01 → 2023-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥4.8bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.2bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥7.4bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss |
| Net income | ¥5.9bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss |
| Total assets | ¥299.4bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥317.3bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥297.3bn | at 2023-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥313.0bn | at 2022-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥311.4bn | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥192.1bn | at 2025-03-31 | Cons. | Liabilities |
| Total liabilities | ¥211.3bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥107.3bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥105.9bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥100.2bn | at 2023-03-31d | Cons. | Net assets |
| Net assets / equity | ¥100.0bn | at 2022-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥103.9bn | at 2021-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥23.1bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥34.7bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥20.1bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥31.1bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥15.1bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥23.2bn | at 2022-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥26.3bn | at 2021-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | −¥8.0bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥23.6bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥3.0bn | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥7.5bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥1.4bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | ¥3.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.8bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.0bn | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥2.0bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥549m | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥6.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥5.8bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥4.1bn | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥8.5bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥2.5bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥149.02 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥115.03 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥92.69 | 2022-04-01 → 2023-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥87.88 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥21.26 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥2,193.96 | at 2025-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,085.09 | at 2024-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,911.44 | at 2023-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,858.86 | at 2022-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,863.77 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 35.4% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.0% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.3% | at 2023-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 31.6% | at 2022-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.1% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 6.9% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 5.7% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 4.9% | 2022-04-01 → 2023-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 4.7% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 1.2% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 3,756 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 3,705 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 3,719 | at 2023-03-31d | Cons. | Number of employees |
| Employees | 3,754 | at 2022-03-31d | Cons. | Number of employees |
| Employees | 3,696 | at 2021-03-31d | Cons. | Number of employees |
| Revenue | ¥7.7bn | 2024-04-01 → 2025-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥8.8bn | 2023-04-01 → 2024-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥5.2bn | 2022-04-01 → 2023-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥4.9bn | 2021-04-01 → 2022-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥2.5bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥6.7bn | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Operating income | ¥8.0bn | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Ordinary income | ¥6.7bn | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥7.9bn | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥4.4bn | 2022-04-01 → 2023-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥4.1bn | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.9bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥6.6bn | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥7.9bn | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Net income | ¥6.6bn | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥7.9bn | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥4.4bn | 2022-04-01 → 2023-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥4.1bn | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥1.8bn | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥75.2bn | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥76.1bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥69.2bn | at 2023-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥69.2bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥66.6bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥21.0bn | at 2025-03-31 | Standalone | Liabilities |
| Total liabilities | ¥23.9bn | at 2024-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥54.2bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥52.2bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥48.3bn | at 2023-03-31d | Standalone | Net assets |
| Net assets / equity | ¥46.3bn | at 2022-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥44.4bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥7.8bn | at 2025-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥5.6bn | at 2024-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥134.93 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥156.33 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥83.57 | 2022-04-01 → 2023-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥75.04 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥33.31 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥45 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥42 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥39 | 2022-04-01 → 2023-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥26 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥12 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,123.29 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,039.86 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥931.75 | at 2023-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥868.78 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥803.59 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 72.1% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 68.6% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 69.8% | at 2023-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 66.9% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 66.7% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 12.4% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 15.8% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 9.2% | 2022-04-01 → 2023-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 9.0% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 4.2% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 51,902,000 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 51,902,000 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 61,224,000 | at 2023-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 61,224,000 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 61,224,000 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 52 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 54 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 54 | at 2023-03-31d | Standalone | Number of employees |
| Employees | 62 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 72 | at 2021-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 97
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2024-04-01 → 2025-03-31 | ¥120m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2024-04-01 → 2025-03-31 | ¥248m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2025-03-31 | 605 pure |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-04-01 → 2025-03-31 | ¥7.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-04-01 → 2025-03-31 | ¥4.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥2.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2025-03-31 | ¥12.8bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-04-01 → 2025-03-31 | −¥78m |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2025-03-31 | −¥13.5bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2025-03-31 | −¥13.5bn |
| Reconciling Itemsreconciling | segment assets | at 2025-03-31 | −¥7.9bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2025-03-31 | ¥55m |
| Medical Products Wholesalereportable segment | capex | 2024-04-01 → 2025-03-31 | ¥3.0bn |
| Medical Products Wholesalereportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥3.2bn |
| Medical Products Wholesalereportable segment | employees | at 2025-03-31 | 2531 pure |
| Medical Products Wholesalereportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥575.4bn |
| Medical Products Wholesalereportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥564.6bn |
| Medical Products Wholesalereportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥10.8bn |
| Medical Products Wholesalereportable segment | segment assets | at 2025-03-31 | ¥279.4bn |
| Medical Products Wholesalereportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥5.2bn |
| Pharmacy Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥88m |
| Pharmacy Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥157m |
| Pharmacy Businessreportable segment | employees | at 2025-03-31 | 504 pure |
| Pharmacy Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥19.6bn |
| Pharmacy Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥19.6bn |
| Pharmacy Businessreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥12m |
| Pharmacy Businessreportable segment | segment assets | at 2025-03-31 | ¥9.4bn |
| Pharmacy Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥251m |
| Veterinary Drugs Wholesale Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥3m |
| Veterinary Drugs Wholesale Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥18m |
| Veterinary Drugs Wholesale Businessreportable segment | employees | at 2025-03-31 | 116 pure |
| Veterinary Drugs Wholesale Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥11.6bn |
| Veterinary Drugs Wholesale Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥11.6bn |
| Veterinary Drugs Wholesale Businessreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥0 |
| Veterinary Drugs Wholesale Businessreportable segment | segment assets | at 2025-03-31 | ¥5.8bn |
| Veterinary Drugs Wholesale Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥314m |
| —segment total | capex | 2024-04-01 → 2025-03-31 | ¥3.1bn |
| —segment total | depreciation | 2024-04-01 → 2025-03-31 | ¥3.4bn |
| —segment total | revenue | 2024-04-01 → 2025-03-31 | ¥606.6bn |
| —segment total | revenue external | 2024-04-01 → 2025-03-31 | ¥595.8bn |
| —segment total | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥10.8bn |
| —segment total | segment assets | at 2025-03-31 | ¥294.5bn |
| —segment total | segment profit | 2024-04-01 → 2025-03-31 | ¥5.7bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2024-04-01 → 2025-03-31 | ¥3.2bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2024-04-01 → 2025-03-31 | ¥3.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2025-03-31 | ¥613.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2025-03-31 | ¥600.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥13.5bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2025-03-31 | ¥307.3bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2025-03-31 | ¥5.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2023-04-01 → 2024-03-31 | ¥94m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2023-04-01 → 2024-03-31 | ¥236m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-04-01 → 2024-03-31 | ¥7.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-04-01 → 2024-03-31 | ¥4.5bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥2.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2024-03-31 | ¥13.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2024-03-31 | −¥109m |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2024-03-31 | −¥13.2bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2024-03-31 | −¥13.2bn |
| Reconciling Itemsreconciling | segment assets | at 2024-03-31 | −¥8.2bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2024-03-31 | ¥90m |
| Medical Products Wholesalereportable segment | capex | 2023-04-01 → 2024-03-31 | ¥4.8bn |
| Medical Products Wholesalereportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥2.8bn |
| Medical Products Wholesalereportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥563.4bn |
| Medical Products Wholesalereportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥552.9bn |
| Medical Products Wholesalereportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥10.6bn |
| Medical Products Wholesalereportable segment | segment assets | at 2024-03-31 | ¥297.5bn |
| Medical Products Wholesalereportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥4.9bn |
| Pharmacy Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥67m |
| Pharmacy Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥149m |
| Pharmacy Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥19.1bn |
| Pharmacy Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥19.1bn |
| Pharmacy Businessreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥12m |
| Pharmacy Businessreportable segment | segment assets | at 2024-03-31 | ¥9.5bn |
| Pharmacy Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥310m |
| Veterinary Drugs Wholesale Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥1m |
| Veterinary Drugs Wholesale Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥16m |
| Veterinary Drugs Wholesale Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥11.0bn |
| Veterinary Drugs Wholesale Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥11.0bn |
| Veterinary Drugs Wholesale Businessreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥0 |
| Veterinary Drugs Wholesale Businessreportable segment | segment assets | at 2024-03-31 | ¥5.4bn |
| Veterinary Drugs Wholesale Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥350m |
| —segment total | capex | 2023-04-01 → 2024-03-31 | ¥4.9bn |
| —segment total | depreciation | 2023-04-01 → 2024-03-31 | ¥3.0bn |
| —segment total | revenue | 2023-04-01 → 2024-03-31 | ¥593.6bn |
| —segment total | revenue external | 2023-04-01 → 2024-03-31 | ¥583.0bn |
| —segment total | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥10.6bn |
| —segment total | segment assets | at 2024-03-31 | ¥312.5bn |
| —segment total | segment profit | 2023-04-01 → 2024-03-31 | ¥5.6bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2023-04-01 → 2024-03-31 | ¥5.0bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2023-04-01 → 2024-03-31 | ¥3.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2024-03-31 | ¥600.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2024-03-31 | ¥587.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥13.2bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2024-03-31 | ¥325.5bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2024-03-31 | ¥5.5bn |
| Medical Products Wholesalereportable segment | employees | at 2025-03-31 | 52 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 2,261
| Item | Context | Value | Unit |
|---|---|---|---|
| Cash and cash equivalents (5-year summary) | Prior2YearInstant | 15147000000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior1YearInstant | 31125000000 | JPY |
| Cash and cash equivalents (5-year summary) | CurrentYearInstant | 20074000000 | JPY |
| Number of employees | Prior4YearInstant | 3696 | |
| Number of employees | Prior3YearInstant | 3754 | |
| Number of employees | Prior2YearInstant | 3719 | |
| Number of employees | Prior1YearInstant | 3705 | |
| Number of employees | CurrentYearInstant | 3756 | |
| Average number of temporary workers | Prior4YearInstant | 1698 | |
| Average number of temporary workers | Prior3YearInstant | 1636 | |
| Average number of temporary workers | Prior2YearInstant | 1607 | |
| Average number of temporary workers | Prior1YearInstant | 1550 | |
| Average number of temporary workers | CurrentYearInstant | 1484 | |
| Net sales (5-year summary) | Prior4YearDuration_NonConsolidatedMember | 2538000000 | JPY |
| Net sales (5-year summary) | Prior3YearDuration_NonConsolidatedMember | 4901000000 | JPY |
| Net sales (5-year summary) | Prior2YearDuration_NonConsolidatedMember | 5161000000 | JPY |
| Net sales (5-year summary) | Prior1YearDuration_NonConsolidatedMember | 8834000000 | JPY |
| Net sales (5-year summary) | CurrentYearDuration_NonConsolidatedMember | 7715000000 | JPY |
| Ordinary income loss (5-year summary) | Prior4YearDuration_NonConsolidatedMember | 1871000000 | JPY |
| Ordinary income loss (5-year summary) | Prior3YearDuration_NonConsolidatedMember | 4085000000 | JPY |
| Ordinary income loss (5-year summary) | Prior2YearDuration_NonConsolidatedMember | 4355000000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YearDuration_NonConsolidatedMember | 7943000000 | JPY |
| Ordinary income loss (5-year summary) | CurrentYearDuration_NonConsolidatedMember | 6675000000 | JPY |
| Net income loss (5-year summary) | Prior4YearDuration_NonConsolidatedMember | 1835000000 | JPY |
| Net income loss (5-year summary) | Prior3YearDuration_NonConsolidatedMember | 4073000000 | JPY |
| Net income loss (5-year summary) | Prior2YearDuration_NonConsolidatedMember | 4355000000 | JPY |
| Net income loss (5-year summary) | Prior1YearDuration_NonConsolidatedMember | 7941000000 | JPY |
| Net income loss (5-year summary) | CurrentYearDuration_NonConsolidatedMember | 6617000000 | JPY |
| Capital stock (5-year summary) | Prior4YearInstant_NonConsolidatedMember | 5000000000 | JPY |
| Capital stock (5-year summary) | Prior3YearInstant_NonConsolidatedMember | 5000000000 | JPY |
| Capital stock (5-year summary) | Prior2YearInstant_NonConsolidatedMember | 5000000000 | JPY |
| Capital stock (5-year summary) | Prior1YearInstant_NonConsolidatedMember | 5000000000 | JPY |
| Capital stock (5-year summary) | CurrentYearInstant_NonConsolidatedMember | 5000000000 | JPY |
| Total number of issued shares (5-year summary) | Prior4YearInstant_NonConsolidatedMember | 61224000 | |
| Total number of issued shares (5-year summary) | Prior3YearInstant_NonConsolidatedMember | 61224000 | |
| Total number of issued shares (5-year summary) | Prior2YearInstant_NonConsolidatedMember | 61224000 | |
| Total number of issued shares (5-year summary) | Prior1YearInstant_NonConsolidatedMember | 51902000 | |
| Total number of issued shares (5-year summary) | CurrentYearInstant_NonConsolidatedMember | 51902000 | |
| Net assets (5-year summary) | Prior4YearInstant_NonConsolidatedMember | 44385000000 | JPY |
| Net assets (5-year summary) | Prior3YearInstant_NonConsolidatedMember | 46251000000 | JPY |
| Net assets (5-year summary) | Prior2YearInstant_NonConsolidatedMember | 48251000000 | JPY |
| Net assets (5-year summary) | Prior1YearInstant_NonConsolidatedMember | 52197000000 | JPY |
| Net assets (5-year summary) | CurrentYearInstant_NonConsolidatedMember | 54226000000 | JPY |
| Total assets (5-year summary) | Prior4YearInstant_NonConsolidatedMember | 66592000000 | JPY |
| Total assets (5-year summary) | Prior3YearInstant_NonConsolidatedMember | 69162000000 | JPY |
| Total assets (5-year summary) | Prior2YearInstant_NonConsolidatedMember | 69162000000 | JPY |
| Total assets (5-year summary) | Prior1YearInstant_NonConsolidatedMember | 76105000000 | JPY |
| Total assets (5-year summary) | CurrentYearInstant_NonConsolidatedMember | 75182000000 | JPY |
| Net assets per share (5-year summary) | Prior4YearInstant_NonConsolidatedMember | 803.59 | |
| Net assets per share (5-year summary) | Prior3YearInstant_NonConsolidatedMember | 868.78 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |